Literature DB >> 23527743

Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage.

Jasmine Nettiksimmons1, Laurel Beckett, Christopher Schwarz, Owen Carmichael, Evan Fletcher, Charles Decarli.   

Abstract

Previous work examining Alzheimer's Disease Neuroimaging Initiative (ADNI) normal controls using cluster analysis identified a subgroup characterized by substantial brain atrophy and white matter hyperintensities (WMH). We hypothesized that these effects could be related to vascular damage. Fifty-three individuals in the suspected vascular cluster (Normal 2) were compared with 31 individuals from the cluster characterized as healthy/typical (Normal 1) on a variety of outcomes, including magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers, vascular risk factors and outcomes, cognitive trajectory, and medications for vascular conditions. Normal 2 was significantly older but did not differ on ApoE4+ prevalence. Normal 2 differed significantly from Normal 1 on all MRI measures but not on Amyloid-Beta1-42 or total tau protein. Normal 2 had significantly higher body mass index (BMI), Hachinksi score, and creatinine levels, and took significantly more medications for vascular conditions. Normal 2 had marginally significantly higher triglycerides and blood glucose. Normal 2 had a worse cognitive trajectory on the Rey's Auditory Verbal Learning Test (RAVLT) 30-min delay test and the Functional Activity Questionnaire (FAQ). Cerebral atrophy associated with multiple vascular risks is common among cognitively normal individuals, forming a distinct subgroup with significantly increased cognitive decline. Further studies are needed to determine the clinical impact of these findings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23527743      PMCID: PMC3751169          DOI: 10.1037/a0031063

Source DB:  PubMed          Journal:  Psychol Aging        ISSN: 0882-7974


  50 in total

1.  Robust smoothness estimation in statistical parametric maps using standardized residuals from the general linear model.

Authors:  S J Kiebel; J B Poline; K J Friston; A P Holmes; K J Worsley
Journal:  Neuroimage       Date:  1999-12       Impact factor: 6.556

2.  Nonparametric permutation tests for functional neuroimaging: a primer with examples.

Authors:  Thomas E Nichols; Andrew P Holmes
Journal:  Hum Brain Mapp       Date:  2002-01       Impact factor: 5.038

3.  Midlife cardiovascular risk factors and risk of dementia in late life.

Authors:  R A Whitmer; S Sidney; J Selby; S Claiborne Johnston; K Yaffe
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

4.  Measures of brain morphology and infarction in the framingham heart study: establishing what is normal.

Authors:  Charles DeCarli; Joseph Massaro; Danielle Harvey; John Hald; Mats Tullberg; Rhoda Au; Alexa Beiser; Ralph D'Agostino; Philip A Wolf
Journal:  Neurobiol Aging       Date:  2005-04       Impact factor: 4.673

5.  Mild cognitive impairment represents early-stage Alzheimer disease.

Authors:  J C Morris; M Storandt; J P Miller; D W McKeel; J L Price; E H Rubin; L Berg
Journal:  Arch Neurol       Date:  2001-03

6.  Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study.

Authors:  M Kivipelto; E L Helkala; T Hänninen; M P Laakso; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

7.  Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden.

Authors:  Charles DeCarli; Evan Fletcher; Vincent Ramey; Danielle Harvey; William J Jagust
Journal:  Stroke       Date:  2004-12-02       Impact factor: 7.914

8.  Association of midlife blood pressure to late-life cognitive decline and brain morphology.

Authors:  G E Swan; C DeCarli; B L Miller; T Reed; P A Wolf; L M Jack; D Carmelli
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

9.  Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study.

Authors:  Tom Jeerakathil; Philip A Wolf; Alexa Beiser; Joseph Massaro; Sudha Seshadri; Ralph B D'Agostino; Charles DeCarli
Journal:  Stroke       Date:  2004-06-24       Impact factor: 7.914

10.  Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease.

Authors:  Natalie L Rasgon; Heather A Kenna; Tonita E Wroolie; Ryan Kelley; Daniel Silverman; John Brooks; Katherine E Williams; Bevin N Powers; Joachim Hallmayer; Allan Reiss
Journal:  Neurobiol Aging       Date:  2009-12-23       Impact factor: 4.673

View more
  19 in total

1.  Development and validation of risk index for cognitive decline using blood-derived markers.

Authors:  Jasmine Nettiksimmons; Hilsa Ayonayon; Tamara Harris; Caroline Phillips; Caterina Rosano; Suzanne Satterfield; Kristine Yaffe
Journal:  Neurology       Date:  2015-01-21       Impact factor: 9.910

Review 2.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

Review 3.  Structural imaging measures of brain aging.

Authors:  Samuel N Lockhart; Charles DeCarli
Journal:  Neuropsychol Rev       Date:  2014-08-22       Impact factor: 7.444

4.  Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.

Authors:  Annie M Racine; Rebecca L Koscik; Sara E Berman; Christopher R Nicholas; Lindsay R Clark; Ozioma C Okonkwo; Howard A Rowley; Sanjay Asthana; Barbara B Bendlin; Kaj Blennow; Henrik Zetterberg; Carey E Gleason; Cynthia M Carlsson; Sterling C Johnson
Journal:  Brain       Date:  2016-06-20       Impact factor: 13.501

Review 5.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

6.  Differential effects of ischemic vascular disease and Alzheimer's disease on brain atrophy and cognition.

Authors:  Ling Zheng; Harry V Vinters; Wendy J Mack; Michael W Weiner; Helena C Chui
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

7.  Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.

Authors:  Emily C Edmonds; Katherine J Bangen; Lisa Delano-Wood; Daniel A Nation; Ansgar J Furst; David P Salmon; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2016-11       Impact factor: 2.892

Review 8.  Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Michael C Donohue; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Paul M Thompson; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

9.  Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.

Authors:  Clifford R Jack; Josephine Barnes; Matt A Bernstein; Bret J Borowski; James Brewer; Shona Clegg; Anders M Dale; Owen Carmichael; Christopher Ching; Charles DeCarli; Rahul S Desikan; Christine Fennema-Notestine; Anders M Fjell; Evan Fletcher; Nick C Fox; Jeff Gunter; Boris A Gutman; Dominic Holland; Xue Hua; Philip Insel; Kejal Kantarci; Ron J Killiany; Gunnar Krueger; Kelvin K Leung; Scott Mackin; Pauline Maillard; Ian B Malone; Niklas Mattsson; Linda McEvoy; Marc Modat; Susanne Mueller; Rachel Nosheny; Sebastien Ourselin; Norbert Schuff; Matthew L Senjem; Alix Simonson; Paul M Thompson; Dan Rettmann; Prashanthi Vemuri; Kristine Walhovd; Yansong Zhao; Samantha Zuk; Michael Weiner
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

10.  Cerebrospinal fluid vascular endothelial growth factor.

Authors:  Peter T Nelson; Gregory A Jicha
Journal:  JAMA Neurol       Date:  2015-05       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.